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Most people appear to stop using cannabis when getting older, but a certain subgroup be-
comes cannabis dependent, has problems in various life areas and needs treatment. Our 
aim is to compare a number of sociodemographic and treatment seeking variables between 
treatment seekers with primary cannabis problems and those with primary alcohol, opiate, 
amphetamine or cocaine problems. Understanding how primary cannabis users seeking 
treatment differ from other treatment seekers may assist clinicians in better tailoring treat-
ment processes to clients’ needs.  
Methods 
For this purpose, intake information on 1,626 persons seeking treatment in one of 16 treat-
ment agencies in the province of Antwerp (Belgium) was registered via an on-line web 
application. Primary cannabis users seeking treatment were compared with primary alcohol, 
opiate, amphetamine and cocaine users by means of bivariate analyses (Chi-square tests 
and analyses of variance), followed by four logistic regression analyses.   
Findings 
14.5% of all clients used cannabis as their primary drug. Compared to primary alcohol, opi-
ate, amphetamine or cocaine users seeking treatment, cannabis users seeking treatment 
appeared to be more often male, younger than 30 years old, Belgian and student. They are 
often referred to treatment by police or justice and 43.6% of them can be considered single-
substance users. Multivariate analyses showed that besides age and sex, using no other 
substances than the primary drug and being registered in outpatient facilities only were sig-
nificant determinants for being a primary cannabis user seeking treatment.   
Conclusions 
Primary cannabis users can clearly be differentiated from other drug users seeking treat-
ment. Although cannabis plays an important part in a polydrug use pattern, persons who 
have cannabis as their primary drug often use only this one substance. Since they regularly 
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have brief contacts with treatment agencies, more research is needed to measure the effect 
of this brief intervention.  
Keywords 
Cannabis, Treatment Demand, Substance Abuse Treatment, Drug Use, Demographics  
Introduction 
In Europe as well as in the United States, cannabis is the most commonly used illegal sub-
stance (1, 2). Based on the available figures, the European Monitoring Centre on Drugs and 
Drug Addiction (1) concludes that the use of cannabis in the European Union is no longer 
rising and that there are signs of stabilisation (and in some countries even a decrease). Most 
people appear to stop using cannabis when they get older and their social roles and respon-
sibilities change (3, 4, 5). Reasons for doing so are changes in living circumstances, peer 
relations or working conditions, but also concerns about health in general and becoming 
cannabis-dependent in particular (6).  
Although some may consider cannabis a ‘soft drug’ with few consequences, regular cannabis 
use has been linked to impairment in cognitive functions, health (e.g. respiratory problems), 
employment and psychological functioning (7). Regular use and especially early onset of 
cannabis use among adolescents is associated with higher levels of other risk behaviours, 
fighting, bullying and school, health and psychological problems (8). On the other hand, 
large-scale studies have demonstrated that the probability of developing cannabis abuse or 
dependence appears to be rather low (5, 9, 10). The risk of developing marijuana depend-
ence among those who have ever tried it, can be situated around 8% to 10% (10, 11). It is 
important to note that since illicit drug use appears to be more transient in nature than, for 
example, alcohol use, it is very unlikely that people will become cannabis-dependent after 
the age of 30 (10).  
Although the overall probability is rather low, various studies carried out in the United States 
demonstrate that the past-year prevalence of marijuana use disorders has slightly risen over 
the past decade. When past-year marijuana users are considered, the past-year prevalence 
of DSM-IV disorders marijuana abuse or dependence has risen from 30.2% to 35.6% (12). 
Several studies show that a minority of persons with a diagnosis of cannabis abuse or de-
pendence seek treatment (13, 14). Furthermore, when they actually do so, a large gap was 
demonstrated between the onset of the disorder and the first drug treatment episode: 5.5 
years for cannabis abuse and 3.1 years for cannabis dependence (14). Still, European 
treatment demand data tend to show a significant increase between 1999 and 2004 regard-
ing the proportion of treatment seekers who use cannabis as their primary drug (1). The 
same evolution can be observed in the United States on the basis of the 2005 Treatment 
Episode Data Set (TEDS) (15). Overall, in 15% to 16% of all treatment requests, cannabis 
appeared to be the primary drug. Obviously, it has to be taken into account that this increase 
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is possibly due to a decrease of the help-seeking behaviour of users of other types of sub-
stances.   
Research on the characteristics of cannabis users seeking treatment is scarce and focuses 
almost entirely on the North American and Canadian situation (16, 17, 18, 19). What we can 
learn from these studies is that cannabis users seeking treatment are more likely to be male, 
single, under the age of 20 and in high school. Legal, school or family-based pressure to en-
ter treatment are commonly present (19). Furthermore, they appear to have problems in 
various life domains: health (especially respiratory problems), psychological status, memory, 
motivation, social interaction, interest in activities, etc. (20). The majority of published studies 
focusing on the characteristics of primary cannabis users seeking treatment and the out-
comes of their treatment are based on experimental marijuana-specific treatment 
programmes (16, 17). Because of the often stringent exclusion criteria that were used to de-
fine the study sample, the findings of those studies regarding socio-demographic and other 
characteristics may not be representative for the cannabis treatment-seeking population as a 
whole.  
Objectives of the study 
As the number of cannabis-related treatment requests rises, it is important to gather back-
ground information on the socio-demographic, substance-related and treatment seeking 
characteristics of this particular group of primary cannabis users seeking treatment since dif-
ferences between cannabis and other drug users may be of clinical importance in developing 
efficacious treatment interventions. A recent review (21) demonstrates that, at this point, no 
single psychotherapy has clearly proven to be more effective than another for the treatment 
of cannabis dependence, and no pharmacological treatment yet exists. Despite the high 
prevalence of cannabis use and dependence, Nordstrom and Levin (21) conclude that the 
phenomenon remains rather understudied compared to other legal and illegal substances. In 
this study, treatment seekers with cannabis as primary drug will be compared with treatment 
seekers who have alcohol, opiates, amphetamines or cocaine as their primary drug in order 
to grasp the unique characteristics of primary cannabis users seeking treatment. Under-
standing how treatment seekers with cannabis as primary drug differ from those having other 
substances as primary drug may assist clinicians in better tailoring treatment processes to 
clients’ needs. After all, it is generally acknowledged that treatment which is adapted to cli-
ents’ needs and characteristics (e.g. type of substance abuse) is more effective (22). 
Methods  
Sample  
This study was set up as a multi-centre, cross-sectional study in inpatient and outpatient 
substance abuse treatment agencies in the province of Antwerp (Belgium). During the six-
month registration period (March 1, 2004 - August 31, 2004), 1,935 treatment requests were 
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registered, representing all treatment requests of persons seeking treatment for problems 
related to legal and/or illicit substances in one of the participating treatment agencies. In to-
tal, six outpatient and ten inpatient treatment agencies or units for substance abusers 
participated in the study, representing nearly all centres in this province where people with 
alcohol or drug problems can get help. We decided not to include the psychiatric wards in 
general hospitals because people with various psychiatric disorders (e.g. anxiety, mood- and 
substance-related disorders) are admitted to this type of treatment setting, and no separate 
treatment programme exists for people with substance-related disorders. Private general 
practitioners, psychologists and psychiatrists were also excluded from the study because 
substance abuse agencies or units were targeted rather than individual therapists. Almost 
two-thirds (63.0%) of all intake interviews took place in residential facilities, with the other 
37.0% in outpatient agencies.  
Procedure  
Information on the treatment seekers’ characteristics was registered during the initial intake 
interview. An initial intake interview was defined as the first face-to-face contact between a 
person requesting treatment and a health care professional (e.g. psychologist, social worker, 
counsellor) in order to bilaterally exchange information. After this initial intake interview, the 
clinician decided together with the person whether treatment was necessary; if so, treatment 
was initiated. Since information was gathered and registered by clinicians, this contributed to 
the collection of high-quality data by persons specialised in this field, who have close con-
tacts with clients (23). On the other hand, registration by clinicians includes the risk of so-
called “registration fatigue”, while staff turnover and the involvement of various persons regis-
tering may hamper perfect standardisation of registration procedures (24). These issues 
were addressed by limiting the registration to a six-month period, organising several training 
sessions, giving financial incentives, elaborating an extended registration manual, and pro-
viding a helpdesk where clinicians could get prompt answers to their questions. Furthermore, 
after finishing the research project, individual feedback was provided to all participating 
treatment agencies regarding the number and characteristics of their respective client popu-
lations, which could serve future service planning and development (25).  
In order to explore the persons’ treatment seeking patterns without violating their privacy, a 
unique client identifier was introduced for this study which permitted tracking of individuals 
across treatment demands and agencies. This identifier, in combination with other stable 
personal information (e.g. year of birth and sex), was also used for eliminating multiple 
counts when analysing characteristics of unique treatment seekers. Although some double 
counts will not have been recognised as such, absolute perfection is neither possible nor re-
quired (26). After all, the main purpose was to reduce the probability of the number of 
multiple counts to a level that is a good estimation of the true number of unique treatment 
seekers (23). Furthermore, this method is also advised by the EMCDDA in order to avoid dis-
tortion of research results.  
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Instrument 
Due to the lack of a common registration tool in Belgian substance abuse treatment (27), a 
specific instrument was developed. The variables included were largely derived from ques-
tions or variables in the ‘Treatment Demand Indicator’ protocol, a common European 
standard manual on treatment demand registration developed by the Pompidou 
Group/European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (23) and from 
items in the European Addiction Severity Index (EuropASI), a semi-structured interview that 
offers the possibility for clinicians and researchers to map the severity of functioning prob-
lems in various life areas (28, 29). All treatment agencies were involved in the development 
and elaboration of the instrument and research design in order to enhance participation. 
Since this was an additional registration (besides the already existing various administrative 
registration procedures in each agency), only a limited number of variables was collected: 
socio-demographic data (sex, age, place of residence, country of birth, employment and liv-
ing situation); substance-related information (primary drug, regular use of various types of 
substances); injecting behaviour (ever, during the last 12 months); previous treatment epi-
sodes; and type of treatment centre (inpatient vs. outpatient). The primary drug was defined 
as the drug that – according to the clinician – causes the person the most problems. This 
definition is in accordance with the guidelines in the EuropASI manual (29).  
For data collection purposes, a secure online web application was developed with consider-
able advantages compared to paper-based registration, e.g. improved data quality and 
communication between clinicians and researchers. A large majority of treatment centres 
made use of the application. Only two treatment centres filled out registration sheets and 
sent them in on a monthly basis to the researchers due to the fact that internet access was 
not readily available.  
Data analysis 
All data were converted to and entered into SPSS, and a thorough data quality check was 
performed. If necessary, unclear or contradictory information was passed on to the person in 
the centre responsible for completion or correction of the registration.  
Sociodemographic and treatment seeking differences between five groups (primary drug: 
alcohol, cannabis, opiate, amphetamine, cocaine) were examined. Other substances (e.g. 
methadone, sedatives, xtc) were less often cited as primary drug and were therefore not in-
cluded in further analyses. For 20 clients, the primary drug was unknown. These data were 
also excluded from further analyses. For categorical variables, chi-square tests were used; 
for continuous variables, analysis of variance (ANOVA) was used. Only results yielding a p-
value < 0.05 were considered statistically significant. When the overall chi-square or F-
statistic was significant, post-hoc tests were used to evaluate the significance of the differ-
ences between pairs of groups. For categorical variables, the test for pairwise comparison of 
column proportions was used, adjusting the p-values for multiple comparisons through the 
Bonferroni method. For continuous variables, the Bonferroni post-hoc test was used. After 
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these bivariate comparisons, a selection of variables was entered in a logistic regression 
model in order to determine which variables were independently associated with being a pri-
mary cannabis user seeking treatment, as compared to four reference groups: primary 
alcohol, opiate, amphetamine or cocaine users seeking treatment. Four logistic regression 
analyses were carried out in order to find the best fitting model that describes the relation be-
tween a dependent binary variable and a fixed set of independent variables. The variables 
that were selected are: age, sex (male/female), Belgium as country of birth (yes/no), living 
together with partner and/or children (yes/no), being currently employed (yes/no), having le-
gal problems (yes/no), regularly using the primary drug only (yes/no), registered in outpatient 
treatment centres only (yes/no), registered more than once (yes/no) and immediate start of 
treatment after intake interview (yes/no). Selection of variables was largely based on previ-
ous research findings. When comparing groups of clients, incomplete registration forms were 




After careful analysis of multiple counts on the basis of the unique client identifier, it was 
concluded that the 1,935 registered treatment requests corresponded to 1,626 unique per-
sons. The majority was registered only once (86.6%), while 9.6% was registered twice, and 
3.8% three or more times. The sample consisted of 26.4% women and 73.4% men. The 
mean age was 36.7 years (SD=12.9). Overall, alcohol was most commonly cited as the pri-
mary drug (n=758; 46.6%), followed by cannabis (n=236; 14.5%), opiates (n=130; 8.0%), 
amphetamines (n=123; 7.6%), and cocaine (n=100; 6.1%). Methadone, sedatives, xtc, multi-
ple substances or other substances were less often cited as primary drug (n=259).  
Sociodemographics of treatment seeking primary cannabis users  
The large majority of primary cannabis users appears to be male, with only 13.1% female 
(Table 1). Compared to the primary alcohol and amphetamine users, this proportion of 
women is significantly lower (29.3% and 34.1% respectively). Primary cannabis users are 
also younger than all other treatment seekers. They have a mean age of 23.6 years and 
81.3% is younger than 30 years old. Only the primary amphetamine users are also generally 
under the age of 30. All other groups have a mean age of 30 years or older. Further, only 
8.6% of the primary cannabis users were not born in Belgium. This is considerably lower 
than the cocaine (18.6%) and opiate (35.9%) subgroups. When the clients’ living, working 
and judicial conditions are considered, we observe that primary cannabis users are more of-
ten still students (in 41.2% of the cases) compared with all other groups, even the 
amphetamine users (18.8%) who have a similar mean age as the cannabis users. The same 
conclusion can be drawn regarding their living conditions: primary cannabis users more often 
live with their parents (52.4%) compared to other treatment seekers. The results also show 
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that both primary cannabis and amphetamine users have in almost half of the cases current 
problems with police or justice. However, different types of legal problems can be observed: 
almost half of the cannabis users having legal problems are involved in the ‘therapeutic ad-
vice’ procedure, while more than a third of the amphetamine users are on probation after 
detention. Therapeutic advice is a measure through which youngsters who come into contact 
with the law because of drug-related offences (possession or use of illicit drugs, predomi-
nantly cannabis) are referred to substance abuse treatment agencies in order to assess 
whether their use is problematic and whether treatment is indicated. This measure also has 
the objective for youngsters to become familiar with the treatment system.  
Substance use patterns of treatment seeking primary cannabis users  
Primary cannabis users – in comparison with primary alcohol users – have higher prevalence 
figures regarding the regular use of amphetamines, hallucinogens, cocaine and ecstasy, but 
lower prevalence figures on the regular use of sedatives. Compared with the other illicit drug 
users, we can observe that they are less likely to regularly use cocaine, opiates and seda-
tives. For the other substances, a more differentiated picture needs to be drawn: regular 
amphetamine use is lower in primary cannabis users than in primary cocaine users, but not 
different from primary opiate users; regular ecstasy use is lower in primary cannabis users 
than in primary amphetamine users but not significantly different from primary cocaine and 
opiate users. Overall, 43.6% of primary cannabis users only uses cannabis regularly and can 
be considered single-substance users, while in nearly all other groups – except for primary 
alcohol users (68.1%) – this figure is remarkably lower: between 17.7% (opiates) and 22.0% 
(cocaine). Also, the group of primary cannabis users has injected significantly less often in 
the past year compared with primary amphetamine, cocaine and opiate users.  
A treatment seeking profile of primary cannabis users  
In only half of the cases primary cannabis users had a treatment history. This was signifi-
cantly lower than in all other groups, since between 72.7% and 81.6% of the other treatment 
seekers were already treatment-experienced. Of all treatment seekers, primary cannabis us-
ers had sought treatment most often in outpatient treatment agencies (in 70.3% of the 
cases). This figure was significantly higher than for alcohol and cocaine users; for ampheta-
mine and opiate users the differences were not significant. In 43.6% of the cases, primary 
cannabis users were referred to treatment by police or justice officials. This is considerably 
higher than among other groups, except for amphetamine users (34.1%). Finally, we also 
looked at the outcome of the intake interview: in a quarter of the cases, primary cannabis us-
ers did not start treatment or were not referred to another treatment centre. The intake 
interview remained ‘without immediate consequence’. For all other groups this figure varied 
between 7.7% and 11.4%.  
Table 1: Comparison of primary cannabis users with primary alcohol, opiate, amphetamine  
or cocaine users (n=1347) 










































         
Sex      33.728 .000 a, c 
Male 86.9 70.7 78.5 65.9 82.0    
Female 13.1 29.3 21.5 34.1 18.0    
         
Age         
< 20 38.1 0.7 2.3 24.8 4.0 326.142 .000 a, b, d 
20-29 43.2 8.5 36.7 47.9 48.0 228.939 .000 a 
30-39 11.9 22.2 43.0 18.2 36.0 56.726 .000 a, b, d 
40-49 6.4 35.5 13.3 7.4 12.0 128.936 .000 a   
> 49  0.4 33.2 4.7 1.7 0.0 212.583 .000 a, b  













292.272 .000 a, b, d 
         
Country of birth         
Belgium 91.4 92.9 64.1 96.7 81.4 110.308 .000 b, d 
         
Living situation         
Alone 22.5 44.2 27.0 23.6 25.5 57.361 .000 a 
With partner and/or 
children 
13.0 39.3 31.0 17.1 25.5 71.926 .000 a, b 
With parents 52.4 6.4 9.5 35.0 25.5 275.958 .000 a, b, c, d 
Homeless 2.6 5.1 12.7 4.1 12.2 24.027 .000 b, d 
         
Employment situation         
Employed 18.6 33.7 24.8 24.8 38.9 25.146 .000 a, d 
Student 41.2 1.2 3.5 18.8 3.2 310.150 .000 a, b, c, d 
Unemployed 23.9 25.5 33.6 35.0 44.2 20.793 .000 d 
Invalidity 13.7 27.6 20.4 17.1 6.3 37.197 .000 a 
         
Legal problems         
None  52.8 88.3 73.3 52.9 79.8 171.737 .000 a, b, d 
Release on bail or 
other conditions await-
ing trial/sentencing 
3.4 2.4 5.8 8.3 5.1 12.999 .011  
Probation after deten-
tion 
9.8 3.7 11.7 17.4 8.1 38.804 .000 a 
Compulsory admission 3.4 3.6 2.5 5.8 3.0 2.189 NS  
Juvenile court 5.5 0.3 0.8 6.6 0.0 46.553 .000 a 
Therapeutic advice 22.6 0.3 0.0 1.7 0.0 231.932 .000 a,c 
         
Regular use sub-
stances 
        
Alcohol (>= 5 glasses a 
day) 
40.3 99.3 29.4 43.3 50.5 600.038 .000 a  
Amphetamines 18.7 4.5 19.5 98.4 30.3 616.082 .000 a, c 
Cannabis 99.6 9.5 39.0 48.8 53.1 673.135 .000 a, b, c, d  
Cocaine 19.1 7.8 48.4 33.9 100.0 487.140 .000 a, b, c 
Ecstasy 19.0 3.6 13.9 41.3 17.2 166.883 .000 a, c 
Hallucinogens 5.6 1.5 9.9 8.3 6.1 32.847 .000 a 
Opiates 1.7 1.3 92.2 10.1 18.0 882.551 .000 b, c, d 
Sedatives 9.0 22.7 30.4 28.2 28.6 33.662 .000 a, b, c, d 
         
Only regular use of 
primary drug  
43.6 68.1 17.7 19.5 22.0 233.711 .000 a, b, c, d 
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Injected during last 
year 
3.4 0.9 37.6 23.7 20.0 234.873 .000 b, c, d 
         
Treatment history 49.1 81.0 81.6 73.6 72.7 97.299 .000 a, b, c, d 
         
Number of registrations 
> 1  
5.9 14.8 12.3 19.5 18.0 18.120 .001 a, c, d 
         
Types of treatment cen-
tres 
        
Inpatient 27.5 77.6 28.5 38.2 51.0 278.227 .000 a, d 
Outpatient 70.3 19.9 66.9 56.1 41.0 273.105 .000 a, d 
Both 2.1 2.5 4.6 5.7 8.0 12.206 NS  
         
Source of referral         
No source of referral 16.1 29.6 38.0 17.1 35.0 33.863 .000 a, b, d 
Immediate surround-
ings 
18.6 18.8 18.6 13.8 13.0 3.565 NS  
Police or justice 43.6 9.9 7.8 34.1 12.0 171.881 .000 a, b, d 
Specialised substance 
abuse treatment 
1.7 2.9 11.6 7.3 15.0 48.173 .000 b, d 
General hospital 3.4 9.1 3.1 2.4 6.0 17.593 .001 a 
General practitioner 4.7 12.0 6.2 6.5 8.0 15.423 .004 a 
Psychiatric hospital  5.5 8.7 2.3 8.1 3.0 11.201 .024  
         
Outcome of intake in-
terview 
        
Start of treatment 69.5 89.1 73.8 73.2 70.0 70.065 .000 a, 
Immediate referral to 
other centre 
4.7 2.9 18.5 15.4 19.0 82.786 .000 b, c, d 
Without consequences 25.8 8.0 7.7 11.4 11.0 57.779 .000 a, b, c, d 
         
a: Significant difference between primary cannabis and primary alcohol users 
b: Significant difference between primary cannabis and primary opiate users 
c: Significant difference between primary cannabis and primary amphetamine users 
d: Significant difference between primary cannabis and primary cocaine users 
Independent determinants of being a primary cannabis user 
Logistic regression analyses (Table 2) were performed in order to identify independent de-
terminants of being a primary cannabis user seeking treatment, while controlling for potential 
effects of other relevant variables. Age was significantly associated with being a primary 
cannabis user compared with three out of four reference groups (primary alcohol, opiate or 
cocaine users seeking treatment): being older decreased the odds of being a primary canna-
bis user. In comparison with primary amphetamine users, age was not a significant 
determinant but sex was all the more: being male increased the odds of being a primary 
cannabis user by about four times. Using no other substances than the primary drug was a 
significant determinant in all four analyses: it significantly increased the odds of being a pri-
mary cannabis user as compared with treatment seekers with other illegal substances as 
primary drug (opiates, amphetamines or cocaine) but decreased the odds of being a primary 
cannabis user as compared to primary alcohol users. Overall, living, working and judicial 
situation were less important determinants, except in the analysis with primary cocaine users 
as reference group: being employed significantly decreased the odds whereas having legal 
problems increased the odds of being a primary cannabis user. Finally, when treatment 
seeking variables are concerned, being registered only in outpatient facilities increased the 
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odds of being a primary cannabis user as opposed to being a primary alcohol or cocaine 
user whereas being registered more than once during the registration period decreased the 
odds as compared to being a primary amphetamine user. 
Table 2: Binary logistic regression analyses presenting Odds Ratios for being a primary cannabis user 
seeking treatment with primary alcohol, opiate, amphetamine and cocaine users seeking treatment as 
reference groups 
 Alcohol Opiate Amphetamine Cocaine 
 Exp(β) 95% CI Exp(β) 95% CI Exp(β) 95% CI Exp(β) 95% CI 
         
Sex: male   1.230  .635 -  2.381  1.658  .752 - 3.655  3.915**  2.117 - 7.240  .966  .416 - 2.317 
Age  .838**  .811 - .865  .902**  .868 - .936  .981  .948 - 1.014  .939**  .902 - .978 
Country of birth: Belgium  1.391  .629  -  3.074  4.982**  2.347 -10.574  .392  .1181 - .300 2.381  .983 - 5.767 
Living situation: with part-
ner and/or children 
 .964  .519  -  1.791  .748  .349 - 1.606  1.306  .600 - 2.841  .889  .396 - 1.996 
Working situation: employ-
ed 
 .436**  .243  -  .782  .810  .402 - 1.630  .620  .329 - 1.167  .214**  .107 - .428 
Legal problems  1.339  .734  -  2.444  1.871  .997 - 3.509  .645  .377 - 1.103 2.214 * 1.165 - 4.434 
Use of primary drug only  .369**  .219  -  .621  4.516**  2.157 - 9.455  3.640**  1.955 - 6.780 2.067 * 1.035 - 4.129 
Registered in an outpatient 
setting only 
 4.748**  2.739  -  8.228  .860  .446 - 1.660  1.611  .118 - 1.611 3.079** 1.606 - 5.902 
Registered more than once  .795  .355  -  1.782  .574  .216 - 1.524  .413 *  .043 - .413  .437  .171 - 1.115 
Immediate start of treat-
ment after intake 
 .732  .363  -  1.476  1.818  .895 - 3.694  1.229  .500 - 1.689 1.844  .907 - 3.751 
Total number of treatment 
seekers included in the 
analysis 
887 329 337 312 
Nagelkerke R² 0.710 0.414 0.242 0.366 
*  Significant at the .05 level 
** Significant at the .01 level 
Discussion 
Prevalence of cannabis as a primary drug within treatment settings 
During the six-month registration period 1,626 unique clients were registered. Alcohol was 
the most commonly cited primary drug (46.6%) followed by cannabis (14.5%), opiates 
(8.0%), amphetamines (7.6%) and cocaine (6.1%). It is striking to observe that when we look 
at the illegal drugs, cannabis is first in line; almost twice as many treatment seekers claimed 
cannabis as their primary drug (14.5%) compared with any of the other illegal drugs. In Euro-
pean treatment demand figures, on the other hand, opiates are still first in line, but the 
number of primary cannabis users is steadily rising (1). Of course, we have to take into ac-
count one of the main limitations of registration research: results are determined to a large 
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extent by the number and types of treatment centres that have participated in the study, e.g. 
the proportion of inpatient versus outpatient centres (30). Still, with this study we covered a 
very wide range of services, as a result of which our figures can be considered representa-
tive for the client population in this particular treatment system.  
Several hypotheses can be formulated regarding the rise of primary cannabis users seeking 
treatment, but thus far no study has been able to indicate which hypothesis is correct (1). Ac-
cording to our opinion, several evolutions are interacting with each other. First, more people 
have started (regularly) using cannabis in the past years, resulting in more people – in abso-
lute numbers – who experience difficulties or problems related to its use and eventually seek 
treatment. This tendency of increased use among the general population is not seen for 
other substances for the moment. Second, several studies have examined the potency of 
cannabis and related changes over the years (30, 31, 32) and found that the potency of can-
nabis has systematically increased, also in the Netherlands, one of Belgium’s neighbouring 
countries. They suggested that this could have an effect on cannabis-related problems and 
treatment demand.  
Characteristics of primary cannabis users seeking treatment 
The objective of this article was to compare treatment seekers with cannabis as primary drug 
with those with alcohol, opiates, amphetamines or cocaine as primary drug on a number of 
sociodemographic and treatment seeking variables. The sociodemographic profile of the 
former emerged as male, younger than 30 years old, Belgian and student. This profile is 
largely consistent with previous research, although the sex differences are more pronounced 
in our study (19). We particularly want to focus attention on cannabis use among students in 
tertiary education. Several American studies have estimated last-year prevalence figures to 
be situated around 30% (34, 35). A recent study in Antwerp (Belgium) among university and 
college students, based on 5,530 questionnaires, demonstrated that 22% of the university 
students had used cannabis in the last year. The authors concluded that students are more 
at risk of using cannabis than their non-college-attending peers since the last-year preva-
lence is considerably higher than the last-year prevalence of cannabis use in the general 
Belgian population (age 18-25): 22% versus 12.2% (36). When these figures are linked to 
our results, it becomes clear that cannabis use among students can result in a number of 
cannabis-related problems and in some cases a need for treatment. Therefore, it would be 
useful to implement prevention campaigns targeted at university and college students and to 
engage in thorough screening and early interventions (37).  
Overall, polydrug use has become the rule rather than the exception. In a society where a 
diversity of psychoactive substances is available, it is easier for users to start using other 
substances that replace or complement their primary drug or to experiment with various 
combinations (38). Our study confirms this finding, except for treatment seekers with alcohol 
or cannabis as primary drug. While about 80% of all treatment seekers with amphetamine, 
cocaine or opiates as primary drug are polydrug users, the percentages among treatment 
seekers with alcohol (31.9%) or cannabis (56.4%) as primary drug are much lower. Further-
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more, multivariate analyses showed that using no other substances than the primary drug 
was a significant determinant for being a primary cannabis user seeking treatment compared 
to the four reference groups (primary alcohol, opiate, amphetamine and cocaine users seek-
ing treatment). On the other hand, cannabis is the substance that is most often used in 
addition to clients’ primary substance, even to a higher degree than alcohol.      
Further, when other characteristics of treatment seekers with cannabis as primary drug are 
concerned, the high number of persons with legal problems (47.2%) and correspondingly 
high number of referrals by police or justice (43.6%) also catches the eye. Other Belgian re-
search has demonstrated that overall most registered drug-related offences were related to 
cannabis (39). Since cannabis is the most widely used illicit substance (2, 40), it is not sur-
prising that the largest share of people who are caught by the police for substance-related 
offences and potentially referred to treatment have cannabis as their problem drug. Further-
more, this high number of referrals by police or justice can partly be explained by the high 
number of young people in the group of treatment seekers with cannabis as primary drug: 
although the possession of small amounts of cannabis is less often prosecuted when there 
are no aggravating circumstances, the possession of cannabis by minors remains a priority 
of police and justice in Belgium.  
Finally, our study also demonstrates that in 25.8% of the cases, the intake interview of treat-
ment seekers with cannabis as primary drug does not result in the start of a treatment 
episode or in the referral to another centre. It would be useful to carry out a study on how 
these persons experienced this brief contact with a treatment agency. Second, in the frame-
work of moving towards more evidence-based prevention, it would be useful to know if this 
particular intervention actually has an effect on youngsters’ cannabis using behaviour, since 
time and resources in treatment services are limited and waiting lists are a reality. In other 
studies, brief treatment interventions have certainly proven to be effective in various situa-
tions and for various target groups, e.g. substance-abusing adolescents and primary care 
populations (41, 42). Consequently, this may also be an effective intervention for (young) 
cannabis users.  
Limitations of the study 
Although this study has several strengths, including the large coverage of participating treat-
ment centres and the conscientious organisation of data collection (e.g. via online web 
application), some limitations need to be mentioned. As reported in the methodology section 
of this paper, we chose to keep the number of variables as limited as possible to ensure 
maximum participation of the treatment centres. As a result, we lack detailed information in 
certain areas, e.g. on substance use patterns (such as sequentiality or simultaneity of poly-
drug use, DSM-IV abuse or dependence diagnoses), treatment history and psychiatric prob-
lems. Second, working with treatment demand data means that the generalisability to other 
samples is not self-evident. Each treatment system has its own characteristics (e.g. admis-
sion and referral policies or connections with the criminal justice system) that influence the 
results. Nevertheless, it is generally acknowledged that treatment sample studies can result 
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in valuable information for further treatment planning and organisation (43). Another limitation 
could be that we relied on self-reported data; biological testing was not used by the register-
ing treatment centres. However, numerous studies have confirmed the validity and reliability 
of self-reported data regarding the use of licit and illicit substances (44, 45, 46). A final limita-
tion is that – in a way – we have reduced and have not sufficiently acknowledged reality by 
creating subgroups via the variable ‘primary drug’ since the large majority of clients are poly-
drug users (47). However, numerous studies have relied on this particular variable to com-
pare (sub)groups of drug users and have found conclusive evidence to support this grouping 
strategy (48, 49, 50). The definition (29) implies that the primary drug is the drug that – ac-
cording to the clinician – causes the person the most problems, compared to other 
substances that a person possibly (mis)uses. These problems can be situated in various life 
areas (employment, social relations, psychological health, physical health), but no hierarchy 
is provided in the EuropASI manual. As a result, it is theoretically possible that – when a per-
son regularly and excessively uses alcohol and occasionally intravenously uses 
amphetamines – the clinician has selected alcohol as primary drug as the intake interview 
has shown e.g. that the person’s alcohol use leads to serious problems with his or her family 
and employer, is closely linked to depressive episodes and driving under the influence of al-
cohol. Of course, the treatment plan will also have to deal with the amphetamine use since IV 
use has severe consequences for a person’s physical health. In case several substances are 
equally causing the person problems, the clinician also has the possibility to indicate “multi-
ple drugs” as primary drug.  
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